SCHEMBL3687153

SCHEMBL3687153

Cc1c(C(=O)O)sc2cc(Cl)c(F)cc12

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 3/20 0.59
MCL1 Q07820 5/20 0.48
BCKDK O14874 2/20 0.48
BCL2L1 Q07817 2/20 0.48
RXFP1 Q9HBX9 3/20 0.45
PKM P14618 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAPK1 P28482 1/20 0.40
TBXAS1 P24557 3/20 0.39
DAO P14920 2/20 0.38
PRNP P04156 1/20 0.36
BCL2 P10415 1/20 0.35
BAD Q92934 1/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3685054 0.81 ALDH1A1 (0.48) GPR35RXFP1MAPK1RAB9ANPC1
SCHEMBL25228985 0.77 MAP2 (0.48) MCL1BCKDKBCL2L1RXFP1MAPK1
SCHEMBL6840187 0.76 MCL1 (0.60) GPR35MCL1BCKDKBCL2L1RXFP1
SCHEMBL14703004 0.75 GPR35 (1.00) GPR35MCL1BCKDKBCL2L1RXFP1
SCHEMBL122587 0.74 GPR35 (0.58) GPR35MCL1BCKDKBCL2L1RXFP1
SCHEMBL2893771 0.74 GPR35 (0.58) GPR35MCL1BCKDKBCL2L1RXFP1
SCHEMBL2895162 0.74 BCKDK (0.67) GPR35MCL1BCKDKBCL2L1RXFP1
SCHEMBL12153769 0.74 MCL1 (0.71) GPR35MCL1BCKDKBCL2L1RXFP1
SCHEMBL3681719 0.74 NPSR1 (0.36) NPSR1
SCHEMBL6840188 0.73 MCL1 (0.60) GPR35MCL1BCKDKBCL2L1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US disclosed
EP-1597248-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-11-23 EP disclosed
WO-2004073606-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG GPR35 160/4885MCL1 4406/4885BCKDK 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.